← back to search

Francesco Rodeghiero

European Science Foundation · IT
Area of research
Genetics · Hematology
Research interest
Research interests include Myeloproliferative Neoplasms: Diagnosis and Treatment, Platelet Disorders and Treatments, Blood Coagulation and Thrombosis Mechanisms, and Chronic Lymphocytic Leukemia Research.
h-index
47
citations
11,248
works
165
NIH funding
primary concept
Medicine
email

Recent publications

Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The <scp>ARES</scp> trial
American Journal of Hematology 2024cited by 20position: middledoi
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
Blood 2020cited by 102position: middledoi
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
Blood Cancer Journal 2018cited by 38position: middledoi
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Haematologica 2016cited by 80position: middledoi
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
Blood Cancer Journal 2015cited by 266position: middledoi
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
Blood 2014cited by 155position: middledoi
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
Leukemia 2013cited by 667position: middledoi
Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
Blood 2012cited by 584position: middledoi
A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
Blood 2012cited by 264position: middledoi
Hydroxyurea‐related toxicity in 3,411 patients with Ph'‐negative MPN
American Journal of Hematology 2012cited by 134position: middledoi
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis
Blood 2012cited by 76position: middledoi
Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients
American Journal of Hematology 2012cited by 60position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Francesco Passamonti · University of Insubria7 papers (2012–2015)Irene Bertozzi · Azienda Ospedaliera Universitaria Senese7 papers (2012–2015)Alessandro M. Vannucchi · All India Institute of Medical Sciences7 papers (2012–2015)Maria Luigia Randi · University of Padua7 papers (2012–2015)Tiziano Barbui · Ospedale Maggiore7 papers (2012–2015) · 7 papers (2012–2015) · 7 papers (2012–2015) · 6 papers (2012–2015)Ayalew Tefferi · Mayo Clinic6 papers (2012–2015)Heinz Gisslinger · Hôpital Saint-Louis6 papers (2012–2015)Alessandro Rambaldi · Astellas Pharma (United States)6 papers (2012–2015)Marco Ruggeri · International Breast Cancer Study Group6 papers (2012–2015)Bettina Gisslinger · Ospedale San Bortolo4 papers (2012–2014) · 3 papers (2012–2014) · 3 papers (2012–2015)Valerio De Stefano · Agostino Gemelli University Polyclinic3 papers (2012–2015)Leonhard Müllauer · University of Dundee2 papers (2012–2013)Silvia Betti · Università Cattolica del Sacro Cuore2 papers (2012–2015)Naseema Gangat · Mayo Clinic in Arizona2 papers (2012–2012) · 2 papers (2013–2014)